WJPR Citation New

  All Since 2020
 Citation  8502  4519
 h-index  30  23
 i10-index  227  96

Submit Manuscript

Best Article Awards

World Journal of Pharmaceutical Research (WJPR) is giving Best Article Award in every Issue for Best Article and Issue Certificate of Appreciation to the Authors to promote research activity of scholar.
Best Paper Award :
Dr. Dhrubo Jyoti Sen
Download Article: Click Here

Search

Track Your Article

Abstract

INVOLUNTARY MUSCULAR MOVEMENTS AS AN ADVERSE REACTION TO SACUBITRIL/VALSARTAN IN A PATIENT WITH CARDIOMYOPATHY AND MULTIPLE COMORBIDITIES: A CASE REPORT

*Pradeep Parashuram Patroti, Gajanan Kumbar, Prajwal S. Hallur, Aftab Dalayat, Prasad Ugaragol, Mallappa Shalavadi

Abstract

Sacubitril/valsartan, an angiotensin receptor–neprilysin inhibitor used in heart failure with reduced ejection fraction, is known to cause hypotension, hyperkalaemia and renal impairment, whereas involuntary muscular movements are a rare neuromuscular reaction reported mainly through postmarketing surveillance. We describe a 43-year-old man with cardiomyopathy, heart failure with recovered ejection fraction, non-cirrhotic portal hypertension, biopsy-confirmed diabetic nephropathy, haemolytic anaemia and miliary tuberculosis who developed non-painful, sporadic involuntary jerks of the upper and lower limbs within 12–72 hours of starting sacubitril/valsartan 24/26 mg twice daily, the lowest recommended dose. Hyponatraemic, uraemic, hypoglycaemic, septic and hepatic encephalopathy and seizure disorder were considered and excluded on clinical and biochemical grounds. The drug was withdrawn, and the movements resolved completely within 24–48 hours without specific treatment; rechallenge was not attempted. Causality was assessed as probable by the World Health Organization–Uppsala Monitoring Centre criteria, with a Naranjo score of 5 and severity level 3 on the Hartwig–Siegel scale. This case extends the reported patient profile to a younger patient with recovered ejection fraction and severe multisystem disease, in whom combined hepatic and renal impairment may have raised exposure to the active metabolite LBQ657. Clinicians starting sacubitril/valsartan in patients with impaired organ clearance should remain alert to this reaction and report suspected cases to pharmacovigilance centres.

Keywords: Sacubitril/valsartan; angiotensin receptor–neprilysin inhibitor; involuntary movements; adverse drug reaction; pharmacovigilance; heart failure with recovered ejection fraction.


[Full Text Article]  [Download Certificate]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More